REACHLINE Human Papillomavirus Rapid Test

Human Papillomavirus (HPV) is a spherical DNA virus widely present in nature, with humans as its sole host. It is highly resistant to drying and can survive for long periods. Currently, over 150 distinct HPV subtypes are known. Based on the severity of the diseases they cause, they can be classified as low-risk or high-risk types.

Clinical symptoms of the diseases include various skin warts such as common warts, flat warts, and plantar warts. Additionally, high-risk HPV types can cause various cancers, including cervical cancer, anal cancer, and penile cancer. Transmission routes primarily include contact transmission, sexual transmission, and mother-to-child transmission, with sexual contact being the most common route of infection. The population is generally susceptible to HPV, but individuals with factors such as early sexual debut, hormonal imbalances, immunosuppression, multiple sexual partners, and smoking are more prone to infection.

Regarding prevention and control, strengthening public health education, promoting sexual health education, and reducing unsafe sexual behaviors are crucial. Vaccination is currently the most effective means of preventing HPV infection. Early identification and timely treatment of HPV infection are also important; antiviral drugs and surgical procedures are common treatment methods. Concurrently, regular screening aids in the early detection of various cancers caused by HPV.

Prevalence

Human Papillomavirus (HPV) is widely present in nature. It was first discovered in specimens from cervical cancer patients in 1977 by German scientist Harald zur Hausen and colleagues. To date, over 150 types have been identified. HPV can be detected in 90% of cervical cancers and 50%-75% of penile cancers, predominantly HPV type 16. Cervical cancer is the second leading cause of cancer death in women globally, with approximately 300,000 deaths annually worldwide; about 50,000 of these deaths occur in China. World Health Organization (WHO) data indicates that approximately 80% of women globally will be infected with HPV at least once in their lifetime.

Recent studies have also found that HPV type 16 can be detected in the tumor tissue of about 20% of patients with head and neck squamous cell carcinomas, such as laryngeal cancer, nasal cavity cancer, and nasopharyngeal cancer. Humans are the sole host for HPV, and HPV infection is extremely common with a high infection rate. Cervical HPV infection generally correlates with age, peaking between 15-25 years, and is the primary causative agent for cervical cancer development.

Pathogenicity

HPV primarily infects human skin and mucosal epithelial cells, typically causing disease only at these sites without causing viremia. The diseases resulting from infection are related to the site of infection:

Cutaneous Infections: Primarily infect squamous epithelium, inducing epithelial cell proliferation and causing various types of skin warts, including common warts, plantar warts, flat warts, and butcher's warts. These are generally benign and self-limiting infections. Common warts and plantar warts are most common on the hands and feet of adolescents (e.g., HPV types 1, 2, 3, 4). Plantar warts are mainly caused by HPV types 1, 2, 4. Flat warts commonly occur on the face, back of hands, and forearms of adolescents (e.g., HPV types 3, 10). Butcher's warts are frequently seen on the hands of butchers and meat handlers (e.g., HPV type 7).

Mucosal Infections: Primarily affect the mucosa of the genital and respiratory tracts, causing genital warts (condylomata acuminata), laryngeal papillomatosis, and cervical cancer, among others. HPV types 6 and 11 are low-risk and cause genital warts, a sexually transmitted disease commonly affecting the genitalia and surrounding skin/mucosa. These are benign lesions and rarely become cancerous. HPV types 6 and 11 can also cause juvenile laryngeal papillomatosis.

Certain high-risk HPV types cause genital malignancies like cervical cancer, vulvar cancer, penile cancer, anal cancer, prostate cancer, and bladder cancer. The types most strongly associated with cervical cancer are HPV 16, 18, 31, 33, and 45. HPV type 16 is detected in up to 50% of cervical cancer patients.

Susceptible Population

The human population is generally susceptible to HPV. However, factors such as early sexual debut, hormonal imbalances, immunosuppression, multiple sexual partners, and smoking increase the risk of infection and disease. Additionally, newborns delivered by mothers with HPV infection are also susceptible to HPV infection.

Infection Symptoms

Following HPV infection, symptoms vary depending on the infection site. Skin and mucosal warts such as common warts, flat warts, and plantar warts may appear. These manifest as papules on the face, back of hands, heels, etc., with a rough or smooth surface, hard texture, and colors like grayish-yellow, brown, or skin-toned. HPV can also cause tumors like cervical cancer, penile cancer, and laryngeal papilloma, which may present as papillary, cauliflower-like, or cockscomb-like growths.

Prevention and Control Measures

HPV infection can lead to various diseases, including warts and cancers. Preventing and controlling HPV infection is crucial for effectively managing conditions like common warts, plantar warts, genital warts, as well as genital cancers such as cervical, vulvar, and penile cancer. Vaccination against HPV is the most effective measure for controlling infection. Besides vaccination, the best prevention method is to avoid direct contact with infected individuals. Contact with personal items and clothing used by infected individuals should also be avoided. Since HPV is a major pathogen for sexually transmitted diseases, emphasizing sexual health education and social management helps reduce transmission.

Vaccine Information

Preventive HPV vaccines are currently available and used clinically. They can prevent HPV infection and related genital precancerous lesions:

Bivalent Vaccine: Prevents HPV types 16 and 18.

Quadrivalent Vaccine: Prevents HPV types 6, 11, 16, 18, and the conditions they cause (genital warts, precancerous lesions, cervical cancer, etc.).

Nonavalent (9-valent) Vaccine: Now available, this nine-in-one vaccine prevents HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. It effectively prevents 80%-90% of cervical cancers, vulvar precancerous lesions, vaginal precancerous lesions, cervical precancerous lesions, genital warts, vaginal cancer, vulvar cancer, anal cancer, and other related diseases caused by these types. It has a good safety profile and can be administered to both males and females aged 9 years and older. However, the nonavalent vaccine cannot treat or prevent already existing infections or conditions like genital warts, cervical cancer, vulvar cancer, or vaginal precancerous lesions.

The REACHLINE Human Papillomavirus Rapid Test is a lateral flow chromatographic immunoassay for the qualitativedetection of Human Papillomavirus type 16 and type 18 antigen in Human genitourinary tract secretions. It is intended to be used as a screening test and as an aid in the diagnosis of infection with Human Papillomavirus.